Sales amounted to DKK 9,545 million for the first six months of 2024, compared with DKK 7,003 million for the first six months of 2023.

'The increase of DKK 2,542 million, or 36%, was mainly due to higher royalty income from DARZALEX (daratumumab) and Kesimpta (ofatumumab) from our collaborations with Janssen Biotech, Inc. (Janssen) and Novartis Pharma AG (Novartis), respectively, and higher net sales of EPKINLY products' says the group.

Royalty income amounted to DKK 7,673 million in the first half of 2024, compared with DKK 5,886 million in the first half of 2023, an increase of DKK 1,787 million (+30%).

Operating profit amounted to DKK 2,441 million in the first half of 2024, compared with DKK 1,885 million. Earnings came to DKK 1,402 million, compared with DKK 75 million.

Genamab has raised its annual targets, expecting 2024 sales of DKK 20.5-21.7 billion, compared with 18.7-20.5 billion previously.

The company has also refined its operating profit target, now anticipating between DKK 5.3 and 7.1 billion, instead of 4.6-7.1 billion.

Copyright (c) 2024 CercleFinance.com. All rights reserved.